A Novel Transapical Transcatheter Aortic Valve System for Treatment of Aortic Stenosis: A Single-Center Early Experience.

IF 2.3 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Clinical Medicine Insights. Cardiology Pub Date : 2025-02-14 eCollection Date: 2025-01-01 DOI:10.1177/11795468251314424

Ping Jin, Hong Guo, Yu Mao, Mengen Zhai, Yang Liu, Jian Yang

{"title":"A Novel Transapical Transcatheter Aortic Valve System for Treatment of Aortic Stenosis: A Single-Center Early Experience.","authors":"Ping Jin, Hong Guo, Yu Mao, Mengen Zhai, Yang Liu, Jian Yang","doi":"10.1177/11795468251314424","DOIUrl":null,"url":null,"abstract":"Background: Transcatheter aortic valve replacement (TAVR) has been widely used to treat patients with aortic stenosis (AS). The anchoring of most transcatheter heart valves (THV) depends on friction with the native aortic valve (AV).Methods: A total of 9 patients with severe AS accepted TAVR using Xcor system with transapical access in our center. Clinical outcomes were collected at baseline, before discharge, and at the 30-day follow-up.Results: All patients achieved procedural success, postprocedural transesophageal echocardiography showed that all of the patients had no/trace paravalvular leakage. The mean AV pressure gradient decreased from 50 mmHg (range 18-76 mmHg) to 10 mmHg (range 8-14 mmHg) (P < .001). At the 30-day follow-up, all patients had an improvement of ⩾1 New York Heart Association functional class (P < .001). The average 6-minute walk distance (377.2 [range 330.0-430.0] m vs 276.1 [range 245.0-320.0] m, P < .001) and Kansas City cardiomyopathy questionnaire score (53.4 [range 45.0-62.0] vs 38.9 [range 35.0-43.0], P < .001) were both improved.Conclusions: Our early experience shows that the Xcor system is safe and feasible in the treatment of patients with severe AS.","PeriodicalId":10419,"journal":{"name":"Clinical Medicine Insights. Cardiology","volume":"19 ","pages":"11795468251314424"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829287/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Medicine Insights. Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/11795468251314424","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Transcatheter aortic valve replacement (TAVR) has been widely used to treat patients with aortic stenosis (AS). The anchoring of most transcatheter heart valves (THV) depends on friction with the native aortic valve (AV).

Methods: A total of 9 patients with severe AS accepted TAVR using Xcor system with transapical access in our center. Clinical outcomes were collected at baseline, before discharge, and at the 30-day follow-up.

Results: All patients achieved procedural success, postprocedural transesophageal echocardiography showed that all of the patients had no/trace paravalvular leakage. The mean AV pressure gradient decreased from 50 mmHg (range 18-76 mmHg) to 10 mmHg (range 8-14 mmHg) (P < .001). At the 30-day follow-up, all patients had an improvement of ⩾1 New York Heart Association functional class (P < .001). The average 6-minute walk distance (377.2 [range 330.0-430.0] m vs 276.1 [range 245.0-320.0] m, P < .001) and Kansas City cardiomyopathy questionnaire score (53.4 [range 45.0-62.0] vs 38.9 [range 35.0-43.0], P < .001) were both improved.

Conclusions: Our early experience shows that the Xcor system is safe and feasible in the treatment of patients with severe AS.

查看原文本刊更多论文

一种治疗主动脉瓣狭窄的新型经根尖经导管主动脉瓣系统：单中心早期经验。

背景：经导管主动脉瓣置换术（TAVR）已被广泛用于治疗主动脉瓣狭窄（AS）患者。大多数经导管心脏瓣膜（THV）的锚定依赖于与原生主动脉瓣（AV）的摩擦。方法：本中心9例重度AS患者采用Xcor系统经根尖通道接受TAVR治疗。在基线、出院前和30天随访时收集临床结果。结果：所有患者均获得手术成功，术后经食管超声心动图显示所有患者无/微量瓣旁漏。平均房室压梯度从50 mmHg（范围18-76 mmHg）降至10 mmHg（范围8-14 mmHg）（P P P P）结论：我们的早期经验表明Xcor系统在治疗严重AS患者中是安全可行的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊